NRS Healthcare is a market-leading outsourced provider of specialist community healthcare equipme...
NRS Healthcare is a market-leading outsourced provider of specialist community healthcare equipment and services to the NHS and local authorities.
PMSI has worked with NRS for almost a decade. We supported LDC’s initial investment in 2012, H2 Equity’s subsequent investment in 2014 and most recently Graphite’s investment in 2019. We continue to support NRS in assessing new growth markets.
We have therefore been trusted by management and its investors to assess NRS’s market environment, competitive landscape, and the impacts of policy changes – each time providing guidance on the achievability of the business plan using our approach of in-depth primary and secondary research.
Since LDC’s initial investment, revenues at NRS Healthcare have more than doubled from £90m in 2013 to £196m in 2019 (14% CAGR) to become one of the largest private NHS providers.
CLS is a leading pre-clinical CRO platform, serving primarily Pharma and Biotechs.
CLS is a leading pre-clinical CRO platform, serving primarily Pharma and Biotechs.
PMSI was asked by the senior management team to provide a strategic assessment of the group, advising where new capabilities need to be added, and how this would improve the structure of the CLS group, backed by Equistone.
Through a mixture of research, analysis, external and internal interviews, PMSI rapidly generated a structure to align the strategic direction of the group. This led to the successful, transformative acquisition of Aquila Biomedical, a pre-clinical in vitro CRO, highly specialised in immuno-oncology – creating one of the largest independent integrated drug discovery platforms globally.
Within the year, the CLS group was acquired by Spectris Plc for £163m (c.18x pro-forma EBITDA)
